Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings

‘We Are Here To Stay’ US Firm Says Of Biosimilar Ambitions

 
• By Dean Rudge
  
Dollars
Amneal is pleased that recent FDA guidelines have contributed to lower biosimilar development costs • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products